EnzymeBioSystems (OTCBB:ENZB) is making a spectacular move up off its $0.50 base on accelerating volume to recent highs well over $2 a share.
In recent news the Company said that while it continues its early-stage research to obtain an Investigational New Drug Application for methyl amooranin, a product the prevention of breast cancer, management is pursuing other opportunities for the Company.
Management has been working on developing proprietary OTC product(s) to be sold under the EnzymeBioSystems label. There are a number of ideas in process, management has not limited itself to any particular OTC product idea. This includes sleep remedies and skin care products.
“As a precautionary note, there are no assurances that the company will ever be able to develop an OTC product where we can obtain distribution or market acceptance,” stated Mr. Gary Rojewski, CEO of EnzymeBioSystems.
EnzymeBioSystems (OTCBB:ENZB) produces specialty enzymes and enzyme related products. The Company plans to use enzyme technologies to develop commercial solutions for different applications within the pharmaceutical industry.
ENZB, designed a drug delivery mechanism, whereby a series of semisynthetic penicillins and cephalosporins containing structural fragments of sarcomycin have been synthesized. Sarcomycin has been around for many years. It is an anti-tumor antibiotic. The problem, is that when it is taken by a cancer patients, and the sarcomycin is given alone, it does not attached to the tumor, but moves throughout the entire body. The penicillin delivers the sacromycin to the tumor where the penicillin attaches to the tumor as proteinase and delievers the sacromycin directly into the tumor.
The Company’s lead product is Amooranin which is isolated from the stem bark of the Indian medicinal plant Amoora rohituka, the product exhibits cytostatic as well as cytotoxic effects in human neoplastic hematopoetic and epithelial cells of diverse origin. Amoorain has also been shown to possess growth inhibitory and apoptosis-inducing effects in several mammary carcinoma cells of human origin.
In animal studies, AMR significantly inhibited the growth of xenografted SW 620 colon carcinoma in mice and reduced tumor size in in rats. Amoorain has also been shown to inhibit the growth of human acute lymphoblastic leukemia cells by pro-apoptotic mechanisms and improve the survival of mice bearing Dalton’s lymphoma ascites tumor cells.
EnzymeBioSystems has found a method for the synthesis of pure Amooranin. The discovery of the method for large-scale synthesis of Amoorain represents a key breakthrough as it eliminates the need of using plant material and hence the dependency on the nature. It also creates the opportunity for animal studies to explore the chemopreventive efficacy of Amooranin.
It is now the Company’s goal to complete animal testing of its synthetic Amooranin to demonstrate its efficacy and lack of toxicity. If the animal studies prove to be successful, the Company plans to submit an IND (Investigational New Drug) application with the FDA to begin Phase I human studies.
To Find out the inside Scoop on ENZB Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
On February 27 ENZB said it ”is a small company with a Big Pharma mentality. “The pharmaceutical industry has changed over the past decade. In the past, Big Pharma would spend a large amount of dollars in researching new pharmaceutical compounds. Today Big Pharma believes it to be more economical to purchase smaller companies that are working to develop and market novel products,” stated Ed Zimmerman, III CFO of EnzymeBioSystems.
The management and affiliates of EnzymeBioSystems have over 50-years of experience working for Big Pharma. This experience helps the company operate with the knowledge gained at Big Pharma.
Amooranin is the Company’s lead pharmaceutical product. Management believes the product can be used in the prevention of breast cancer and is working to obtain the necessary studies to apply for an Investigational New Drug for the product. Management has sourced the pre-clinical product batch and is negotiating with Contract Research Organizations (CRO) on the two species animal studies.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $38 million market valuation ENZB does have $344,000 in the treasury and little debt. This is an exciting story developing in small caps and the Company knows how to market itself and build a successful run; investors have to be impressed with the way this one moves and holds its gains. We will be updating on ENZB when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ENZB.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in ENZB either long or short and we have not been compensated for this article.